1-3 of 3
Michael Fridrik, MD
Close
Sort by
Journal Articles

Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial

Heinz Ludwig, MD, Eberhard Gunsilius, MD, Michael Fridrik, MD, Richard Greil, Andreas Petzer, MD, Thomas Kühr, Univ. Doz. Dr., Stefan Knop, MD, Martin Schreder, MD, Elisabeth Rauch, Mag., Wolfram Poenisch, MD, Niklas Zojer, MD
Journal: Blood
Blood (2016) 128 (22): 3335.
https://doi.org/10.1182/blood.V128.22.3335.3335
Published: 2016
Journal Articles

Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14)

Michael Fridrik, MD, Andreas L Petzer, MD, Felix Keil, MD, Wolfgang Willenbacher, MD, Ulrich Jäger, MD, Alois Lang, MD, Johannes Andel, MD, Otto Krieger, MD, Wilhelm Oberaigner, Richard Greil, MD
Journal: Blood
Blood (2010) 116 (21): 1766.
https://doi.org/10.1182/blood.V116.21.1766.1766
Published: 2010
Journal Articles

Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study

Alexander Egle, MD, Lukas Weiss, M.D., Thomas Melchardt, M.D., Eberhard Gunsilius, MD, Andreas L Petzer, M.D., Michael Fridrik, MD, Alois Lang, MD, Otto Krieger, M.D., Josef Thaler, M.D., Richard Greil, MD
Journal: Blood
Blood (2010) 116 (21): 1380.
https://doi.org/10.1182/blood.V116.21.1380.1380
Published: 2010